SYDNEY SHIVERS: Open Payments
NPI 1053017616 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,415 in 48 payments from 11 companies in 2025. Trend: 2023 $696 · 2024 $631 · 2025 $1,415
Food & beverage: $1,415
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $820 |
| Gilead Sciences, Inc. | 4 | $175 |
| Ipsen Biopharmaceuticals, Inc | 4 | $120 |
| Janssen Biotech, Inc. | 3 | $69 |
| Aimmune Therapeutics, Inc. | 3 | $54 |
| QOL Medical, LLC | 1 | $40 |
| GENZYME CORPORATION | 1 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| Fresenius Kabi USA, LLC | 1 | $27 |
| Ardelyx, Inc. | 1 | $23 |
Products named: RINVOQ, SKYRIZI, LINZESS, IQIRVO, TREMFYA, ZENPEP, CREON, Sucraid.
Industry payments across TX — which companies pay providers there.
